JP2018533557A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533557A5 JP2018533557A5 JP2018517626A JP2018517626A JP2018533557A5 JP 2018533557 A5 JP2018533557 A5 JP 2018533557A5 JP 2018517626 A JP2018517626 A JP 2018517626A JP 2018517626 A JP2018517626 A JP 2018517626A JP 2018533557 A5 JP2018533557 A5 JP 2018533557A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- group
- calcitonin
- antibody
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562237624P | 2015-10-06 | 2015-10-06 | |
| US62/237,624 | 2015-10-06 | ||
| PCT/US2016/055502 WO2017062456A2 (en) | 2015-10-06 | 2016-10-05 | Biomarkers related to interleukin-33 (il-33)-mediated diseases and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018533557A JP2018533557A (ja) | 2018-11-15 |
| JP2018533557A5 true JP2018533557A5 (enExample) | 2019-11-14 |
| JP6858182B2 JP6858182B2 (ja) | 2021-04-14 |
Family
ID=57223756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517626A Active JP6858182B2 (ja) | 2015-10-06 | 2016-10-05 | インターロイキン３３（ｉｌ−３３）媒介疾患に関するバイオマーカーおよびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10005834B2 (enExample) |
| EP (1) | EP3359567A2 (enExample) |
| JP (1) | JP6858182B2 (enExample) |
| KR (1) | KR102687412B1 (enExample) |
| CN (1) | CN108137682B (enExample) |
| AU (1) | AU2016333903B2 (enExample) |
| CA (1) | CA3000725A1 (enExample) |
| EA (1) | EA201890891A1 (enExample) |
| HK (2) | HK1259386A1 (enExample) |
| MA (1) | MA50638A (enExample) |
| MX (1) | MX2018004170A (enExample) |
| WO (1) | WO2017062456A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE064292T2 (hu) | 2013-12-26 | 2024-03-28 | Mitsubishi Tanabe Pharma Corp | Humán anti-IL-33 semlegesítõ monoklonális antitest |
| SG11201605580RA (en) | 2014-01-10 | 2016-10-28 | Anaptysbio Inc | Antibodies directed against interleukin-33 (il-33) |
| US11708608B2 (en) | 2014-11-10 | 2023-07-25 | Genentech, Inc. | Therapeutic and diagnostic methods for IL-33-mediated disorders |
| JP6929771B2 (ja) | 2014-11-10 | 2021-09-01 | ジェネンテック， インコーポレイテッド | 抗インターロイキン−３３抗体及びその使用 |
| JP6858182B2 (ja) | 2015-10-06 | 2021-04-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | インターロイキン３３（ｉｌ−３３）媒介疾患に関するバイオマーカーおよびその使用 |
| SG11201808693WA (en) | 2016-04-27 | 2018-11-29 | Pfizer | Anti-il-33 antibodies, compositions, methods and uses thereof |
| WO2017189805A1 (en) | 2016-04-27 | 2017-11-02 | Abbvie Inc. | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
| MX2019012171A (es) * | 2017-04-13 | 2019-11-25 | Regeneron Pharma | Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1. |
| WO2018231827A1 (en) | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| WO2019045075A1 (ja) * | 2017-08-31 | 2019-03-07 | 田辺三菱製薬株式会社 | Ｉｌ－３３アンタゴニストを含む子宮内膜症治療剤 |
| CN109061139A (zh) * | 2018-06-19 | 2018-12-21 | 温州医科大学附属第医院 | 血清炎性生物标志物在防治急性缺血性脑梗死中的应用 |
| TWI861073B (zh) * | 2019-03-21 | 2024-11-11 | 美商再生元醫藥公司 | 含有抗il-33抗體之穩定調配物 |
| EP4114414A4 (en) * | 2020-03-06 | 2024-03-27 | The Regents of The University of Michigan | SERINE PROTEASE INHIBITORS FOR SUPPRESSING OR PREVENTING ANAPHYLACTIC REACTION |
| EP4118114A1 (en) | 2020-03-13 | 2023-01-18 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| JP7578943B2 (ja) * | 2020-07-13 | 2024-11-07 | 学校法人自治医科大学 | 褥瘡治療剤 |
| CN114814242B (zh) * | 2022-06-10 | 2025-04-01 | 中日友好医院(中日友好临床医学研究所) | 一种诊断慢性阻塞性肺疾病患者肌肉减少症的血液学标志物 |
| WO2024163181A1 (en) * | 2023-01-31 | 2024-08-08 | Vivacelle Bio, Inc. | Compositions and methods for treating hyperprocalcitonemia |
| KR102834740B1 (ko) * | 2023-04-10 | 2025-07-17 | 아주대학교산학협력단 | Hsp10 또는 이의 항체를 유효성분으로 포함하는 만성 자발적 두드러기의 진단을 위한 바이오마커 조성물 |
| WO2026007411A1 (zh) * | 2025-02-11 | 2026-01-08 | 广州医科大学 | 抗IL1RL1/IL-33/NF-kB抗体和使用其治疗急性髓性白血病的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4227454C1 (de) * | 1992-08-19 | 1994-02-03 | Henning Berlin Gmbh | Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens |
| NZ549040A (en) * | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| WO2010025393A2 (en) * | 2008-08-28 | 2010-03-04 | The Regents Of The University Of California | Protein biomarkers and methods for diagnosing kawasaki disease |
| JO3532B1 (ar) * | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| JP6404314B2 (ja) * | 2013-03-15 | 2018-10-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｉｌ−３３拮抗薬とその使用法 |
| JP6715767B2 (ja) * | 2013-10-23 | 2020-07-01 | ジェネンテック， インコーポレイテッド | 好酸球性疾患の診断及び治療方法 |
| JP6858182B2 (ja) | 2015-10-06 | 2021-04-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | インターロイキン３３（ｉｌ−３３）媒介疾患に関するバイオマーカーおよびその使用 |
-
2016
- 2016-10-05 JP JP2018517626A patent/JP6858182B2/ja active Active
- 2016-10-05 CN CN201680058610.4A patent/CN108137682B/zh active Active
- 2016-10-05 MX MX2018004170A patent/MX2018004170A/es unknown
- 2016-10-05 KR KR1020187009724A patent/KR102687412B1/ko active Active
- 2016-10-05 WO PCT/US2016/055502 patent/WO2017062456A2/en not_active Ceased
- 2016-10-05 EA EA201890891A patent/EA201890891A1/ru unknown
- 2016-10-05 CA CA3000725A patent/CA3000725A1/en active Pending
- 2016-10-05 HK HK19101754.3A patent/HK1259386A1/zh unknown
- 2016-10-05 MA MA050638A patent/MA50638A/fr unknown
- 2016-10-05 EP EP16790463.0A patent/EP3359567A2/en active Pending
- 2016-10-05 AU AU2016333903A patent/AU2016333903B2/en active Active
- 2016-10-05 US US15/285,772 patent/US10005834B2/en active Active
- 2016-10-05 HK HK18115046.2A patent/HK1255972A1/zh unknown
-
2018
- 2018-05-21 US US15/985,660 patent/US10851158B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fulkerson et al. | Targeting eosinophils in allergy, inflammation and beyond | |
| JP2020513404A5 (enExample) | ||
| CN110167963B (zh) | 治疗发炎病况的方法 | |
| Izuhara et al. | IL-4 and IL-13: their pathological roles in allergic diseases and their potential in developing new therapies | |
| RU2731713C2 (ru) | Применение il-18-связывающего белка (il-18bp) при воспалительных заболеваниях | |
| JP6858182B2 (ja) | インターロイキン３３（ｉｌ−３３）媒介疾患に関するバイオマーカーおよびその使用 | |
| JP2016536332A5 (enExample) | ||
| RU2016134838A (ru) | Дипептидил пептидаза-4 (dpp4/cd26) как периферический биомаркер активации il-13 в астматическом легком | |
| Hernandez‐Santana et al. | Current perspectives on the interleukin‐1 family as targets for inflammatory disease | |
| JP2017509692A5 (enExample) | ||
| JP2009526756A (ja) | Ｉｌ−３１ｒａアンタゴニストおよびｏｓｍｒｂアンタゴニストを用いて神経組織における疼痛および炎症を治療する方法 | |
| JP2008502366A5 (enExample) | ||
| HUE034005T2 (en) | Therapies for improving lung function | |
| JP2016529232A (ja) | サイトカインアンタゴニストの標的化 | |
| RU2009120202A (ru) | Способы и композиции для лечения и мониторинга лечения связанных с il-13 расстройств | |
| EP3102601B1 (en) | Novel assay to detect human periostin | |
| KR20240049348A (ko) | 항-인터루킨-33 항체를 사용한 만성 폐쇄성 폐질환의 치료 | |
| AU2023329162A1 (en) | Treatment of asthma with an anti-interleukin-33 antibody | |
| Mitchell et al. | Anti-IgE and biologic approaches for the treatment of asthma | |
| TWI870471B (zh) | 全身性硬化症治療用醫藥組合物 | |
| CN108135913A (zh) | 治疗和/或预防特应性皮炎的il-17c拮抗剂 | |
| CN117264053B (zh) | 白介素-9的抗体及其用途 | |
| US20230091430A1 (en) | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Ra1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION | |
| US20250277042A1 (en) | TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Ra1 ANTIBODY OR BINDING FRAGMENT THEREOF | |
| CN116940379A (zh) | 在过敏群体中使用抗IL-13Rα1抗体或其结合片段治疗特应性皮炎 |